GABA.nu

Neurodegeneration is a global societal crisis, affecting an increased number of people each year. Despite decades of research, effective therapeutic treatments for diseases like Alzheimer’s and Parkinson’s are still lacking, forcing biotech and pharma companies to pursue an out-of-the-box approach. One of these is Gabather, a Swedish biotech developing drugs

Gabather’s target engagement study with the lead candidate GT-002, a treatment for neuropsychiatric disorders, is expected to produce its first results by the end of the year. This according to the company’s CEO, Michael-Robin Witt, who joined BioStock for an interview. Läs mer

Swedish biotech Gabather has received the approval from the Portuguese authorities to go ahead with a target engagement study to complete the phase I evaluation of GT-002, the company’s candidate targeting mood disorders. As patient recruitment for the study proceeds, BioStock got in touch with CEO Michael-Robin Witt to learn